Prognostic factors in uterine sarcomas: Restrospective study of 21 years at the Hospital Clinic i Provincial of Barcelona;Factores pronósticos en los sarcomas uterinos: Estudio retrospective de 21 años en el hospital Clínic i Provincial de Barcelona

Medicina Clinica

Volumn 111, Issue 5, 1998, Pages 172-176

  Rovirosa, Ángeles ^a   Ordi, Jaume ^a   Ascaso, Carlos ^b   Casals, Juan ^a   Lejarcegui, Antonio ^a   Iglesias, Javier ^a   Estapé, Jorge ^a   Biete, Albert ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PROGNOSIS; SARCOMA; TIME; TUMOR RECURRENCE; UTERUS CANCER;

ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; SARCOMA; TIME FACTORS; UTERINE NEOPLASMS;

EID: 2542513237     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Rovirosa A. Biete A. Sarcomas uterinos: un reto para el oncólogo, Neoplasia 1995; 12: 151-153.
2. Silverberg SG. Kurman RJ. Tumors of the uterine corpus and gestational trophoblastic disease. En: Rosai J, editor. Atlas of tumor pathology. 3rd series. Washington. DC: Armed Forces institute of Pathology, 1991; 13-14.
3. UICC TNM Atlas. Illustrated guide to the TNM/p TNM-Clasiffication of Malignant Tumours Nueva York Springer-Verlag, 1992; 193-197.
4. Armitage P, Berry G. Estadistica para la investigación biornedica. Barceiona: Edinones Doyma. BCN. 1992.
5. Cox DR, Oakes D. Analisys of survival data. Londres: Chapman and Hall, 1984.
6. Major FJ. Blessing JA, Silverberg SG, Morrow CP, Creasman WT, Currie JL et al Prognostic factors in early stage uterine sarcoma. A Gynecologic Oncology Group Study Cancer 1993; 71 (Supl): 1.702-1.709.
7. Salazar OM, Dunne ME. The role of radiation therapy in the management of uterine sarcomas. Int J Rad Oncol Biol Phys 1980; 5: 899-902.
8. Punnonen R. Lauslahti K. Pystinen P. Kauppila O. Uterine sarcomas. Ann Chirurg Gynecol 1985; 74 (Supl): 11-14
9. Gadduci A, Landoni F, Sartori E, Zola P, Maggino T. Lissoni A et al. Uterine leiomyosarcoma: analysis of treatment failures ano survival. Gynecol Oncol 1996; 62: 25-32.
10. Nielsen SN, Podratz KC, Scheithauer BW, O'Brien PC Clinicopathologic analysis of uterine malignant mixed Müllenan tumors. Gynecol Oncol 1989; 34: 372-378.
11. Salazar OM, Bonfiglic TA, Patten SF, Keller BE, Feldstein M, Dunne ME et al. Uterine sarcomas. Natural history treatment and prognosis. Cancer 1978; 42: 1.152-1.160.
12. George M, Pejovic M, Krarnar A. Uterine sarcomas: prognostic factors and treatment modalities-study on 209 patients. Gynecol Oncol 1986; 24: 58-67.
13. Mantravadi RVP, Bardawi WA, Lochman DJ, Liebner EJ, Townsend ER, Chao JH et al. Uterine sarcomas: an analysis of 69 patients Int J Rad Oncol Biol Phys 1981; 7: 917-922.
14. Schwartz Z, Dgani R, Lancet M, Kessler I, Uterine sarcoma in Israel: a study of 104 cases. Gynecol Oncol 1985; 20: 354-363.
15. Salazar OM, Bonfiglio TA, Patten SF, Keller BE, Feldstein M. Dunne ME et al Uterine sarcomas. Analysis of failures with special emphasis on the use of adjuvant radiation therapy. Cancer 1978; 42: 1.161-1.170.
16. Olàh KS, Blunt HGS, Dunn JA, Kelly K, Chan KK. Retrospective analysis of 318 cases of uterine sarcoma Eur J Cancer 1991; 27: 1.095-1.099.
17. Echt G, Jepson J, Steel J, Langholz B, Luxton G, Hernandez W et al. Treatment of uterine sarcomas. Cancer 1990; 66; 35-39
18. Moskovic E, Macsweeney E. Law M, Price A. Survival, patterns of spread and pronostic factors in uterine sarcoma: a study of 76 patients. Br J Radiol 1993; 66: 1.009-1.015.
19. Marchese MJ, Liskow AS, Crum CP, McCaffrey RM, Frick HC Uterine sarcomas: a clinicopathologic study. 1965-1981. Gynecol Oncol 1984; 18: 299-312.
20. Vongtama V, Karlem JR, Piver SM, Tsukada Y, Moore RH. Treatment, results and prognostic factors in stage I and II sarcomas of the corpus uteri. AJR 1976; 126: 139-147.
21. Perez CA, Askin F, Bagian RJ, Kao MS, Kraus FT, Pérez BM et al. Effects of irradiation on mixed Müllerian tumors of the uterus Cancer 1979; 43: 1.274-1.284.
22. Harlow BL, Weils NS, Lofton S, The epidemiology of sarcomas of the uterus JNCI 1986; 76: 399-402.
23. Olah KS. Leiomiosarcomas have a poorer prognosis than mesodermal tumors when adjustin for known prognostic factors: the result of a retrospective study of 423 cases of uterine sarcoma. Br J Obstet Gynecol 1992; 99: 590-594.
24. Gilbert HA, Kagan AR, Lagasse L, Jacobs MR, Tawa K. The value of radiation therapy in uterine sarcoma. Obstet Gynecoi 1975; 45: 84-88.
25. Sorbe B. Radiotherapy and/or chemotherapy as adjuvant treatment of uterine sarcomas Gynecol Oncol 1985; 20: 281-289.
26. Van Nagell JR, Hanson MB. Donaldson ES, Gallion HH. Adjuvant vincristine, dactinomycin and cyclophosphamide therapy in stage I uterine sarcomas. A pilot study Cancer 1986; 57: 1.451-1.454.
27. Disaia PJ, Castro R. Rutlerdge FN. Mixed mesodermal sarcoma of the uterus Cancer 1973; 117: 632-636.
28. Wronski M, De Paima P, Arbit E. Leiomyosarcoma of the uterus metastatc to the brain: a case report and a review of the litherature. Gynecol Oncol 1994; 54: 237-241.
29. Wolfson AH, Wolfson DJ, Sittler SY, Breton L, Markoe AM, Schwade JG et al. A multivariate analysis of clinicopathologic factors for predicting outcome in uterine sarcomas. Gynecol Oncol 1994; 52: 56-62.
30. Liu FS, Kohler MF, Marks JR, Bast RC, Berchuck A Mutation and over expression of the p53 tumor suppressor gene frequently occurs in uterine and ovarian sarcomas Obstet Gynecol 1994; 83: 118-124.